Blume Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Blume Capital Management’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-150	Closed	–	–	310
2015 Q1	$0	Buy	150 +100	+200%	+$70	﹤0.01%	343
2014 Q4	$0	Buy	+50	New	+$34	﹤0.01%	305

Other funds holding GCVRZ

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Blume Capital Management's GCVRZ Position: Q2 2015 in Review

Blume Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2015, closing a stake of 150 shares.

Blume Capital Management first reported a position in GCVRZ in Q4 2014 and held it in 2 quarters. The position peaked at $0 in Q1 2015. 116 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2015.

Blume Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q2 2015 after selling out during the quarter.
Blume Capital Management sold 150 Sanofi Contingent Value Rights shares in Q2 2015.
Blume Capital Management first reported a position in Sanofi Contingent Value Rights in Q4 2014 and held it in 2 quarters.
Blume Capital Management's Sanofi Contingent Value Rights position peaked at $0 in Q1 2015.
116 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2015.

Based on Blume Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.